Although human genetics can help identify new drug targets, the best way to prioritize genes as therapeutic targets is uncertain. A new study describes a framework to prioritize potential targets by integrating genome-wide association data with genomic features, disease ontologies and network connectivity.
This is a preview of subscription content, log in via an institution to check access.
References
Plenge, R. M., Scolnick, E. M. & Altshuler, D. Nat. Rev. Drug Discov. 12, 581–594 (2013).
Nelson, M. R. et al. Nat. Genet. 47, 856–860 (2015).
Fang, H. et al. Nat. Genet. https://doi.org/10.1038/s41588-019-0456-1 (2019).
Rossin, E. J. et al. PLoS Genet. 7, e1001273 (2011).
de Lange, K. M. et al. Nat. Genet. 49, 256–261 (2017).
Sun, B. B. et al. Nature 558, 73–79 (2018).
Raychaudhuri, S. et al. Nat. Genet. 41, 1313–1318 (2009).
Okada, Y. et al. Nature 506, 376–381 (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing Interests
R.M.P. is a full-time employee at Celgene.
Rights and permissions
About this article
Cite this article
Plenge, R.M. Priority index for human genetics and drug discovery. Nat Genet 51, 1073–1075 (2019). https://doi.org/10.1038/s41588-019-0460-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41588-019-0460-5
- Springer Nature America, Inc.
This article is cited by
-
Priority index for critical Covid-19 identifies clinically actionable targets and drugs
Communications Biology (2024)
-
Genetic and Gene Expression Resources for Osteoporosis and Bone Biology Research
Current Osteoporosis Reports (2023)
-
The impact of rare protein coding genetic variation on adult cognitive function
Nature Genetics (2023)
-
Recent advances in understanding the genetic basis of systemic lupus erythematosus
Seminars in Immunopathology (2022)
-
Expanded COVID-19 phenotype definitions reveal distinct patterns of genetic association and protective effects
Nature Genetics (2022)